IMP3 and neoplasm: Examination of immunohistochemical samples of various types of ovarian cancers, probing for CTGF expression of IMP1, IMP2, and IMP3, revealed that IMP2 was expressed in over 5% of all tumor types analyzed, with the highest levels observed in the micropapillary variant of serous borderline tumors and high-grade serous carcinoma (HGSCs), where expression ranged from 98 to 100% [117].